- Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Expires: February 28, 2011 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Weyer Christian

2. Date of Event Requiring Statement (MM/DD/YYYY) 6/1/2010

3. Issuer Name and Ticker or Trading Symbol

AMYLIN PHARMACEUTICALS INC [AMLN]

(Last) (First) (Middle)

9360 TOWNE CENTRE DR

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Sr. VP Research & Development /

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2326 ⁽¹⁾	D
Common Stock	4815	I	by ESOP ⁽²⁾

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Incentive Stock Option (right to buy)	⁽³⁾	10/4/2011	Common Stock	5300	$5.73	D
Incentive Stock Option (right to buy)	⁽³⁾	3/4/2016	Common Stock	6252	$9.02	D
Incentive Stock Option (right to buy)	⁽³⁾	6/28/2012	Common Stock	3375	$10.94	D
Incentive Stock Option (right to buy)	⁽³⁾	1/26/2011	Common Stock	15000	$11.5625	D
Incentive Stock Option (right to buy)	⁽³⁾	8/2/2012	Common Stock	4600	$11.95	D
Incentive Stock Option (right to buy)	⁽³⁾	5/25/2015	Common Stock	4132	$16.54	D
Incentive Stock Option (right to buy)	⁽³⁾	2/2/2017	Common Stock	7360	$18.01	D
Incentive Stock Option (right to buy)	⁽³⁾	5/12/2013	Common Stock	6820	$18.85	D
Incentive Stock Option (right to buy)	⁽³⁾	8/31/2014	Common Stock	3467	$19.79	D
Incentive Stock Option (right to buy)	⁽³⁾	5/3/2014	Common Stock	6182	$22.6	D
Incentive Stock Option (right to buy)	⁽³⁾	3/4/2015	Common Stock	3973	$24.87	D
Incentive Stock Option (right to buy)	⁽³⁾	3/7/2017	Common Stock	1484	$36.9	D
Incentive Stock Option (right to buy)	⁽³⁾	5/16/2016	Common Stock	3680	$41.34	D
Non-Qualified Stock Option (right to buy)	⁽³⁾	3/4/2016	Common Stock	13748	$9.02	D
Non-Qualified Stock Option (right to buy)	⁽³⁾	5/25/2015	Common Stock	10868	$16.54	D
Non-Qualified Stock Option (right to buy)	⁽³⁾	2/2/2017	Common Stock	19340	$18.01	D
Non-Qualified Stock Option (right to buy)	⁽³⁾	5/12/2013	Common Stock	2180	$18.85	D
Non-Qualified Stock Option (right to buy)	⁽³⁾	8/31/2014	Common Stock	6533	$19.79	D
Non-Qualified Stock Option (right to buy)	⁽³⁾	5/3/2014	Common Stock	2818	$22.6	D
Non-Qualified Stock Option (right to buy)	⁽³⁾	3/4/2015	Common Stock	16027	$24.87	D
Non-Qualified Stock Option (right to buy)	⁽³⁾	3/7/2017	Common Stock	12516	$36.9	D
Non-Qualified Stock Option (right to buy)	⁽³⁾	5/16/2016	Common Stock	14320	$41.34	D

Explanation of Responses:
( 1)	Includes 412 shares acquired pursuant to the Company's 401(k) plan which fully vested four years from the date of the reporting person's participation in the 401(k) plan.
( 2)	Represents shares acquired pursuant to the Company's ESOP. These shares fully vest four years from the date of the reporting person's participation in the ESOP in four equal annual installments and are generally distributed upon termination of employment.
( 3)	25% of shares vest one year from date of grant and the remainder vest monthly over the next three years becoming fully vested four years from date of grant.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Weyer Christian 9360 TOWNE CENTRE DR SAN DIEGO, CA 92121			Sr. VP Research & Development

Signatures
By: /s/James R. Oehler, Attorney-in-Fact For: Christian Weyer		6/9/2010
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.